Alizyme Share Discussion Threads

[birdie4] 15/7/2009 21:10

And no doubt qaz will come along with a few of his aliases and put a bullish spin on it.

[ecohouse] 15/7/2009 14:43

What would the price recover to if the resolutions are approved must be questions all investors and watchers are asking.

[city chappy] 15/7/2009 14:26

Fair point trout.

Takeda might give AZM a small amount of working cash now in exchange for giving AZM a smaller milestone when Cetilistat Japan reports next year. Takeda would have to assess the risk but they seem pretty confident in Cetilistat and it is underpinned with Orlistats longstanding approval and use.

What you said about "a company alizyme are in discussion with for a deal or takeover ---- could extend to alizyme a short-term secured line of credit" would be quite logical under the current circumstances and could be deducted from the amount a company paid on conclusion of a deal. ULURU extended a $1m short credit line to York Pharma when they were in merger discussions only withdrawing the credit when the discussions did not conclude.

There is still the chance of a Placing for up to £1.45m once the necessary AGM resolutions are approved on 29th July.

[mad mike] 15/7/2009 14:09

Tim's "immense contribution to Alizyme":-
While Tim has been there, Alizyme have raised a total of £131M in funding, but Alizyme are now only worth under £6M. I make that an "immense contribution" towards a destruction in value of more than £125M. That is a colossal figure.

Clearly, the £125M loss isn't all down to Tim, but he has to take a large share of the blame.

[bryant551] 15/7/2009 14:07

Has the corpse stopped twitching yet?

[vow] 15/7/2009 14:00

Why on earth would Takeda give Alizyme credit? If AZM go under they go under and Takeda still retain the rights. They can then discuss new terms with whoever siezes the assets.

If Takeda lend AZM money and AZM go under then Takeda lose that money.

[troutfish] 15/7/2009 13:50

city chappy another possibility is that a company alizyme are in discussion with for a deal or takeover or an existing partner like Takeda could extend to alizyme a short-term secured line of credit.

[silverbackalpha] 15/7/2009 13:30

doctor: I hardly think blaming someone who many people consider to be a complete lair is totally irrational or unusual behaviour.

he told me personally that negotiations were late stage and progressing.

Now he is probaly on a beach in honolulu with a couple of million in the bank and no deals to speak of after 4 years. Yet the company is facing bankruptcy or delisting.

What evidence do you actually need to see? Its not rocket science mate. It happened with Royal Bank of Scotland and Marconi. Its the stock market.

[dunderheed] 15/7/2009 12:58

Re post 23948 - well I must be a fool then!!
But thanks t_d - could I reply with the following retort? Perhaps you were a bit of a 'fool' over on prm recently - I assume this - by virtue of you over valuing the revenues for the prm blockbuster products recently and over the (many!) years?!

[prambigear] 15/7/2009 12:56

Could someone please check the pulse of AZM? I am worried it might already be dead.

[silverbackalpha] 15/7/2009 12:40

I would be gratefull if everyone would use this thread from now on and keep this on topic.

[dunderheed] 15/7/2009 11:55

Actually this is a better one though!!

Commenting on today's announcement, Alan Goodman said:


"On behalf of the Board, I would like to thank Tim for his commitment and
immense contribution to Alizyme from its inception and wish him every success
for the future."

[silverbackalpha] 15/7/2009 11:53

Alan Goodman, founder and chief executive of venture capitalist Avlar, has spearheaded a number of biotechnology companies including Acambis, Oxford BioMedica, Intercytex and Cenes Pharmaceuticals.

The 55 year-old grew up in Ilford and left school aged 16, trained as an accountant and moved into biotech in the 1980s. Besides collecting fast cars, he has houses in Portugal, Grand Cayman and Cambridge, the latter having a separate dressing room for ties. He talks about the drug industry, and those silk ties.


Related Articles
Market report Q: If UK biotech were a medical patient, what do you think its chances would be?

A: With a maturing industry backed by brilliant science, my diagnosis would indicate a good prognosis for a long, fulfilling life.

Q: Is Aim an ideal home for biotech companies?

A: Yes, it has good advisers and an improving number of institutional investors, although there are still too few specialist healthcare funds who really understand biotechs.

Q: What helps drive a biotech company over the long-term?

A: Medical products that are successful in late stage clinical trials are the key drivers. Some people put great store in licensing deals but this does not always guarantee best value to the biotech company in the longer term.

Q: But haven't clinical trials got bad publicity from the recent TeGenero "Elephant Man" drug?

A: Drugs do fail in clinical trials but not usually so spectacularly. However, interfering with this particular mechanism strikes me as inherently very risky.

Q: What will the impact of this high-profile case be?

A: A much more difficult regulatory environment may be brought in for such super-affinity antibody drugs. Esoteric science might look exciting but when it is clinically unproven it will have a very low probability of success.

Q: What is the next major drug likely to be?

A: I think the real breakthroughs will come from using synthetic drugs derived from the study of epigenetics, that is the manipulation of genes that cause disease, targeted on cancer.

Q: Will there ever be a cure for HIV/Aids and if so, when?

A: A cure for HIV is a tough one and I believe many years away. However, prevention of HIV infection, for example through vaccines, is much more promising and should be the way to go.

Q: When you were a child would you have believed you could be doing what you are today?

A: No. But I grew up wondering why such great British discoveries and inventions seemed to be capitalised on by America: computers, jets, hovercraft etc.

Q: You drive Ferraris and wear ties which have pictures of naked women. Please elaborate.

A: I love fast and beautiful cars, the adrenalin rush it gives you on the track. As for the ties, I was told you can tell a person by how he dresses and in particular by the tie he wears. I now have more than 200 and all hand-painted silk.

[silverbackalpha] 15/7/2009 11:51

Does anyone have any idea of Alan Goodmans credentials and experience?

Clearly a buyer and seller of companies. Based on its current form Alizyme is only worth fireside values.

Alan Goodman (CEO and Finance Director)
Over the last 18 years Alan Goodman has founded or co-founded many biotechnology and healthcare companies, including Agricultural Genetics Company, Medeva plc, Chiroscience Group plc, Peptide Therapeutics (now Acambis plc), Oxford BioMedica plc, CeNeS Pharmaceuticals plc, Core Group plc and Amura Limited. He was non-executive Chairman of Oxford BioMedica plc and is currently chairman of CeNeS Pharmaceuticals plc.

[capricious] 15/7/2009 08:44

No posts for 6 days, must be a record, normally there are at least some acid remarks flying around... guess everyone is waiting for the fat lady to stop singing.

[dunderheed] 14/7/2009 13:03

bloody hell 'seized' assets - then I assume they are 'liquidised' - as per another post on this or other thread!!

Doesn't look very promising for azm does it?!

Or, they may get the relatively small amount of cash required to limp along to Ph III results in Jap and things will look a bit brighter?

[silverbackalpha] 14/7/2009 12:54

QAZ: give it up will you. In administration the company assets are siezed so shareholders get left with nothing probably as it has always been a virtual company.

[city chappy] 14/7/2009 09:15

But lets see if Alizyme get the AGM resolutions passed on 29th July to enable them to raise another £1.45m. That might be enough to keep them as a going concern until Cetilistat Japan reports next year or they do another deal for something.

[city chappy] 14/7/2009 09:08

On your last point, we know Alizyme could receive a further $32m in milestone payments plus double digit royalties on sales from Takeda if Cetilistat passes Phase 3 in Japan next year. If the Phase 3 results are successful and Alizyme are in Administration at that time, the Company would still exist so the money would go onto its balance sheet. The company would then become a going concern again and the Administrators would have to consider whether to re-list it (probably on AIM) with the current shareholdings preserved. Alternatively they could try to sell the Company or its drugs, either before or after the Phase 3 Cetilistat Japan results; and Takeda would have to pay the Cetilistat Japan milestone and sales royalties to whoever subsequently owned Alizymes rights to Cetilistat. Personally I do not think the latter approach would be in shareholders best interests.

My feeling is that if Alizyme goes into Administration after August 2009, it would be best to keep the Company on ice in Administration until Takeda report Phase 3 Cetilistat next year (the trial finishes in July 2010) which has a very good chance of being a positive trial result meaning Alizyme would receive substantial milestone and sales payments putting them on a sound financial footing. A company can be kept in Administration for 12 months, or longer with creditors or a Courts permission.

"Administration buys time for a Company, perhaps allowing it to get out of trouble and trading again or for the administrator to rescue the company as a going concern".

(Harris Lipman, Chartered Accountants and Insolvency Practitioners)

Alizyme is perhaps unusual in this respect, in that there is a very real chance of a substantial payment stream to them arising from Cetilistat in a relatively short time after potentially going into Admnistration, meaning the Company could be rescued as a going concern.